Latest and live tenders published in australia. Click on any tender to view further details.

falling number fn is a global industry standard used to quantify detrimental pre-harvest sprouting phs in wheat, as early release from seed dormancy leads to significant effects on end product quality. however, a low falling number can also be caused by the trait of late maturity alpha-amylase lma, with some wheats having a genetic predisposition to accumulate low levels of starch digesting enzymes during grain filling in the absence of sprouting. lma susceptibility is currently a classification criterion for milling wheat in australia. investment description this investment is one of three interrelated investments aimed at managing and eliminating the effect of late maturity alpha-amylase lma in wheat through improved phenotyping and modelling: proc- 9176016 lma project a – improved phenotyping for late maturity alpha-amylase lma susceptibility in wheat proc- 9176017 lma project b – a novel high-throughput, low-cost test to determine cause of starch damage in wheat grain; and lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat. this tender is for the development of a rapid, mobile, low-cost test for starch degradation in wheat grains which can also determine the cause of damage as lma or phs. such a test will be valuable to breeders and pre-breeders seeking to determine the cause of starch damage in breeding material and research populations in the field, increasing the speed at which lma susceptibility can be controlled by genetics. the technology could also be used by growers to aid post-harvest decision making and by grain receivers to rapidly and reliably determine starch damage. it is expected that the successful applicant will propose an innovative approach that may include imaging science, biochemistry and/or molecular biology. the proposed approach may also borrow from other disciplines such as medical sciences, food sciences, physics and engineering. a proof of concept of the proposed approach will be highly regarded in assessment. the tender is open to private, public and private-public partnerships. expected outcome by 2030, late maturity alpha-amylase lma risk is managed within the australian wheat industry as to maximise genetic gains and minimise downgrades to improve enduring profitability for australian growers. intermediate outcome by 2023, australian industry will have access to accurate, high-throughput screening tools for lma expression that are employable early in breeding programs, research programs and applicable to a more cost effective, higher throughput lma classification screen; growers will have the ability to determine starch damage of grain on-farm; and the industry as a whole will have access to accurate field risk profiles of lma to inform decision making. this will be achieved through the three interrelated investments.

provision of innovative solutions to enhance the department’s unified communications.

brain cancer is the sixth leading cause of cancer burden and there are more than 100 types of brain cancer and other central nervous system cancers. these cancers carry high rates of morbidity and mortality. the five-year relative survival rate for brain cancer is low, at around 22 per cent. the young are disproportionately affected by brain cancer and brain cancer kills more children in australia than any other disease. despite improvements in patient care and support, survival rates for brain cancer have remained relatively unchanged for the past 30 years. the australian brain cancer mission the mission was announced on 29 october 2017 and aims to double survival rates and improve the quality of life for patients with brain cancer over ten years to 2027, with the longer term aim of defeating brain cancer. as at july 2019, $124.7m had been committed to the mission through co-investments from philanthropy, non-government organisations and governments, including $58.35m from the australian government through the medical research future fund mrff. cancer australia is responsible for administering the mission, supported by a strategic advisory group msag. a national brain cancer research roundtable was convened in 2017 bringing together people affected by brain cancer and their families, leading australian and international researchers, clinicians, advocacy and philanthropic groups. this roundtable provided the framework for delivery on the aim of the mission and developed a research roadmap that articulates the mission’s investment strategies. conducting an ‘analysis of australian brain cancer platforms and technologies’ is one of the early and immediate priorities for implementation outlined in the research roadmap. the purpose of the analysis is to inform future national infrastructure requirements and their use; identify networking strategies to enhance utilisation for platform and technology systems, and reduce duplication in effort; facilitate better coordinated use of platforms and technologies which will play a significant role in supporting brain cancer research, clinical trials, early detection, diagnosis, treatment and clinical care for children, adolescents and young adults aya, and adults with brain cancer for the next 3 – 5 years, and to 2027. scope: the scope of the analysis will cover platforms and technologies applicable to children, aya and adults with brain cancer across the brain cancer continuum of care, which for the analysis, will include brain cancer research, clinical trials, early detection, diagnosis, treatment, and clinical care. outcomes and reporting requirements: the analysis will inform future national infrastructure requirements, including how resources can be coordinated to play a significant role in supporting the brain cancer continuum of care for children, aya, and adults. the analysis will also identify existing platforms and technologies, as well as potential new platforms and technologies. in undertaking this work, the contractor will be required to provide cancer australia with monthly updates by teleconference, two progress reports, a draft final report and a final report. the two progress reports, the draft final report and the final report will also be considered by msag. the final report will include: 1.a review outlining brain cancer platforms and technologies that are currently available nationally and internationally, and how they are being used in australia; 2.a review of platforms and technologies currently used in cancer research and clinical trials, and where relevant, how these platforms and technologies can be incorporated across the brain cancer continuum of care to inform potential future investments under the mission over the next 3 - 5 years; and to 2027; 3.a review and the analysis of consultations with relevant experts identifying current platforms and technologies, and potential new platforms and technologies, that could inform the next investments under the mission to support the brain cancer continuum of care in australia, specifically: a. what is needed over the next 3 - 5 years; and b. what is on the horizon to 2027; and 4.an analysis of consultations with relevant experts identifying the workforce requirements, capacity, capability and training needs for the next 3 - 5 years and up to 2027, to support future investments in brain cancer platforms and technologies. 5.a gap analysis to inform future requirements across the brain cancer continuum of care in the next 3 – 5 years, and to 2027. the gap analysis will include: a.approaches to enhance utilisation of platform and technology system networks; b.proposals for how current and potential new platforms and technologies utilising large data sets and bioinformatics, can aid in achieving the aim of the mission; c.potential strategies for reduction of any identified duplications in resources in relation to brain cancer platforms and technologies across the continuum of care; and d.potential strategies to facilitate more efficient coordinated use of brain cancer platforms and technologies. 6.a cost-benefit analysis for upscaling current platforms and technologies, and introducing potential new platforms and technologies, to fill identified validated gaps from the above gap analysis. the cost-benefit analysis will include the costs and benefits to patients and the healthcare system in the next 3 – 5 years, and up to 2027, to inform potential future investments under the mission. 7.a plan for upscaling existing platforms and technologies, and the introduction of potential new platforms and technologies, including considerations for the identified critical parameters and elements, required for the upscaling and introduction of these platforms and technologies, to achieve expansion of the brain cancer continuum of care in the next 3 – 5 years and up to 2027. partnerships: cancer australia encourages the partnering of different organisations, departments, and groups to bring together the necessary skills and experiences to provide a tender to undertake the analysis. the organisational structure and management of staff involved in the partnership should be outlined in the tender. timeframe: the project is planned to commence in november 2019 and to be completed within six months of the start date. funding of up to $450, 000 gst inclusive has been provided from the department of health to cancer australia for the purpose of procuring a suitably qualified organisation to undertake this work.

scientific engineering services ses is a high end professional engineering and fabrication capability within the research services division of the defence science and technology group with a mission to provide integrated, multidisciplinary, leading edge, rapid response and innovative scientific engineering solutions to complex problems. the commonwealth seeks a capable and adaptable engineering service provider to augment ses’ aps workforce and to deliver timely and effective engineering services which meet current and future engineering requirements across multiple technology areas.

provision of internal audit services, further details of the requirement are set out in schedule 1 statement of requirement.

supply and delivery of: unprinted plastic dual frequency proximity cards proximity cards; and blank plastic pvc cards pvc cards

provision of logistics and letter services under a panel arrangement. the services are separated into 3 categories: general warehousing and distribution of publications and forms; personalisation and mailing of letters; bulk distribution of digital communication.

provision of printing and production services under a panel arrangement. the services are separated into 16 different categories: print on demand; digital black and colour printing and finishing – small format up to a3; digital black and colour printing and finishing – large format above a3; sheet offset black and colour printing and finishing <1, 000 units; sheet offset black and colour printing and finishing >1, 000 units; heatset web / coldset web black and colour printing and finishing; form printing and finishing; envelope printing and finishing; file cover printing and finishing; security documents printing and finishing; corporate merchandise; specialised printing services; custom finishing services; duplication services; braille and specialist services; and customised plastic products.

developers, builders and owners that have dwellings or land that meets the requirements to tender for proc-35694.

provide consultancy services the development of design guidelines at angle park sa